Andrew Alliance S.A., a Geneva, Switzerland-based robotics company that is improving repeatability with an innovative approach to liquid handling with conventional laboratory pipettes, recently raised $14m in Series C funding.
The C-round investment brings together a strategic mix of globally recognized life sciences market leaders, along with private equity investors and including existing investors. Backers included leading life sciences enterprises- Tecan Group, the Waters Corporation, Inpeco, Rancilio Cube, Sam Eletr Trust and Omega Funds.
The company intends to use the funds for continuous product innovation and strategic industry partnerships and extension of its close collaboration with customers worldwide to refine future offerings.
“We are delighted to expand our team of investors and partners with the industry’s most recognized companies,” said Piero Zucchelli, CEO and a co-founder of Andrew Alliance. “It’s particularly meaningful that both Tecan and Waters appreciate how we’re making robotics accessible to more scientists.”
The Tecan Group is the world leader for automated liquid handling solutions, and Waters has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for nearly 60 years. Both companies are considered technology leaders in their respective fields.
Led by Piero Zucchelli, CEO, Andrew Alliance is advancing a new class of robots that improve the repeatability, performance and speed of liquid handling and rapidly transforming bench research in hundreds of pharmaceutical, diagnostic and academic laboratories worldwide, by eliminating routine pipetting errors and time-consuming manual efforts.